Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1

RIPK1 and RIPK3, two closely related RIPK family members, have emerged as important regulators of pathologic cell death and inflammation. In the current work, we report that the Bcr-Abl inhibitor and anti-leukemia agent ponatinib is also a first-in-class dual inhibitor of RIPK1 and RIPK3. Ponatinib...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cell Rep
Main Authors: Najjar, Malek, Suebsuwong, Chalada, Ray, Soumya S., Thapa, Roshan J., Maki, Jenny L., Nogusa, Shoko, Shah, Saumil, Saleh, Danish, Gough, Peter J., Bertin, John, Yuan, Junying, Balachandran, Siddharth, Cuny, Gregory D., Degterev, Alexei
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494889/
https://ncbi.nlm.nih.gov/pubmed/25801024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2015.02.052
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki